May 2020 Briefing – Diabetes & Endocrinology
Here are what the editors at HealthDay consider to be the most important developments in Diabetes & Endocrinology for May 2020. This roundup includes...
Metformin Recalled Due to Potential Cancer-Causing Chemical
Recall is for all lots of metformin hydrochloride extended-release tablets 500 mg from Apotex
Tooth Loss More Prevalent in Adults With Chronic Disease
Prevalence of edentulism, severe tooth loss ≥50 percent higher for adults with RA, asthma, diabetes
Improving Glycemic Control May Also Aid COVID-19 Outcomes
Insulin infusion may reduce risk for severe disease in those with hyperglycemia and COVID-19
9.5 Percent Uninsured in U.S. From January Through June 2019
Overall, 13.7 percent of adults aged 18 to 64, 4.4 percent of children aged 0 to 17 were uninsured
Links Found Between Leaders of Medical Associations, Industry
Most leaders have ties to industry; considerable variation seen among 10 medical associations in U.S.
Only One in Four U.S. Hospitals With ICUs Have Tele-ICU Services
Wide regional variation seen for availability of telehealth outpatient visits, tele-ICU services
New Medicare Benefit Would Limit Insulin Copays to $35 a Month
Benefit will be voluntary; Medicare recipients must pick an insurance plan that provides it
High Prevalence of Primary Aldosteronism Observed
Adjusted prevalence estimates of aldosteronism increase in parallel with hypertension severity
Weight in Adolescence Tied to Early-Onset Type 2 Diabetes
Higher risk for type 2 diabetes during young adult years tied to body mass index during adolescence
